Skip NavigationSkip to Content
Return Return to Search Results

Novel aryl diketo-containing inhibitors of HIV-1 integrase

  1. Author:
    Pais, G. C. G.
    Burke, T. R.

  2. Author Address

    NCI, Ctr Canc Res, Med Chem Lab, NIH, POB B,Bldg 376,Boyles St, Frederick, MD 21702 USA NCI, Ctr Canc Res, Med Chem Lab, NIH, Frederick, MD 21702 USA Burke TR NCI, Ctr Canc Res, Med Chem Lab, NIH, POB B,Bldg 376,Boyles St, Frederick, MD 21702 USA
    1. Year: 2002
  2. Journal: Drugs of the Future
    1. 27
    2. 11
    3. Pages: 1101-1111
  4. Type of Article: Review
  1. Abstract:

    HIV-1 integrase is a promising therapeutic target for the development of drugs to treat HIV infection. Aryl diketo-based analogs, disclosed independently by scientists from Merck and Shionogi pharmaceutical companies, are a unique class of compounds that exhibit potent integrase inhibition and display good antiviral effects in HIV-infected cells. The progress of Merck's L-870810 and Shionogi's S-1360 to phase 11 clinical trials has promised the inclusion of integrase inhibitors in "cocktail" combination therapies in the near future. This review presents a critical overview of research related to this new class of integrase inhibitors.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at FrederickClose Button

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel